Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Epoxomicin has been used:as an ubiquitin–proteosome system (UPS) inhibitor in pheochromocytoma PC12 cellsas a proteasome inhibitor in mammary epithelial MCF-10A cellsas a proteasome inhibitor in chymotryptic assay in cardiomyocytes

Biochem/physiol Actions

Epoxomicin binds covalently to the catalytic subunits of proteasome. It forms an adduct with target proteins. It inhibits chymotrypsin-like activity of the proteasome. Epoxomicin also inhibits the nuclear factor κ light chain enhancer of activated B cells (NF-κB) mediated proinflammatory signalling pathway. It is also a potent antitumor and anti-inflammatory agent.

Epoxomicin, a natural product isolated from Actinomyces sp., is a cell-permeable, potent, selective and irreversible proteasome inhibitor.

General description

Epoxomicin is a linear peptide consisting of a threonine or serine residue with α′, β′-epoxyketonederived from leucine or a γ,δ-dehydroleucine. It is a natural product isolated fromActinomycessp., and is a cell-permeable, potent, selective and irreversible proteasome inhibitor.

Packaging

50 µg in glass bottle